US · Healthcare · Medical Instruments & Supplies
EPS came in at -0.67 against a street estimate of -0.59 — a miss of 13.6%.
Analysts rate Kestra Medical Technologies, Ltd. Common Stock a strong buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $30.00.
| Fund | Stake |
|---|---|
| Bain Capital Investors LLC | 42.95% |
| T. Rowe Price Associates, Inc. | 10.18% |
| FMR Inc | 9.76% |
| Andera Partners | 4.66% |
| Yu Fan | 3.89% |
| Brown Advisory Holdings Inc | 2.94% |
| BlackRock Inc | 2.88% |
| Eventide Asset Management, LLC | 2.47% |
| Document | Date |
|---|---|
| Proxy statement · Q3 2026 | 2026-07-28 |
| Annual report FY2026 | 2026-07-14 |
| Results announced · Q3 2026 | 2026-07-14 |
| Quarterly report · Q1 2026 | 2026-03-17 |
| Results announced · Q1 2026 | 2026-03-17 |
| Quarterly report · Q4 2025 | 2025-12-11 |
| Results announced · Q4 2025 | 2025-12-11 |
| Material agreement · Q4 2025 | 2025-12-04 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Kestra Medical Technologies, Ltd. Common Stock — free to start.
Google PlayApp StoreData updated 2026-08-05.